Invasive lobular carcinoma (ILC) accounts for approximately 10% to 15% of all breast malignancies. This subtype exhibits unique biological behaviors compared to invasive ductal carcinoma. Specifically, invasive lobular carcinoma metastases often appear in unusual sites like the stomach, ovaries, and peritoneum. These lesions frequently mimic primary gastrointestinal or gynecological cancers. Therefore, clinicians must remain vigilant when evaluating patients with a history of ILC.

Detecting Invasive Lobular Carcinoma Metastases

Diagnostic imaging often fails to identify these metastatic sites early. Because ILC cells grow in a single-file pattern, they rarely form large, cohesive masses. Consequently, traditional CT scans and PET imaging may appear negative even during active progression. Furthermore, biochemical markers like Cancer Antigen 15-3 (CA 15-3) often rise before radiologic evidence emerges. Physicians should prioritize histopathological evaluation if a patient reports unexplained abdominal pain or bloating. Early endoscopy and biopsies are essential for distinguishing metastatic disease from primary GI tumors.

Management of multifocal metastases requires a multi-modal approach. Systemic therapies, including endocrine agents and CDK4/6 inhibitors, remain the cornerstone of treatment. However, some cases may require surgical intervention for symptomatic relief or diagnosis. For example, bilateral salpingo-oophorectomy can reveal occult ovarian involvement that imaging missed. Continuous monitoring and a high index of clinical suspicion are vital for improving patient outcomes in these complex scenarios.

Frequently Asked Questions

How do the metastatic patterns of ILC differ from IDC?

While invasive ductal carcinoma commonly spreads to the lungs, liver, and brain, ILC has a higher affinity for the gastrointestinal tract, peritoneum, and reproductive organs. These atypical sites often lead to misdiagnosis as primary abdominal cancers.

What role does CA 15-3 play in monitoring ILC?

A rising CA 15-3 level often serves as an early indicator of disease progression. It may precede visible changes on a CT scan or ultrasound by several months, prompting earlier investigative procedures like endoscopy.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional relationship. Always seek the advice of a qualified healthcare provider regarding any medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Karkeabadi N et al. Invasive lobular carcinoma of the breast with multifocal gastrointestinal, ovarian, and peritoneal metastases: a case report. J Med Case Rep. 2026 Mar 07. doi: 10.1186/s13256-026-05952-w. PMID: 41795110.
2. Kokkali S, et al. Gastrointestinal Metastases From Lobular Breast Carcinoma. Semantic Scholar. 2024.
3. StatPearls. Lobular Breast Carcinoma. NCBI Bookshelf. 2023.